PKI 14-22 amide, myristoylated

PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB) . PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs[1][2][3].

Product Specifications

CAS Number

[201422-03-9]

UNSPSC

12352209

Hazard Statement

H302, H315, H319

Target

Epigenetic Reader Domain; Flavivirus; PKA

Type

Peptides

Related Pathways

Anti-infection; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pki-14-22-amide-myristoylated.html

Purity

99.65

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@H](C(N)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C53H100N20O12

Molecular Weight

1209.49

Precautions

H302, H315, H319

References & Citations

[1]L Ydrenius, et al. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol. 2000 Apr;67 (4) :520-8.|[2]Cheng F, et al. Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol. 2018 Jan 30;92 (4) :e02019-17.|[3]Gabra BH, et al. Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res. 2008 Jun 27;1217:70-7.